Berotralstat effectiveness and safety in patients with hereditary angioedema with normal C1 inhibitor
Long-term prophylactic berotralstat was effective in reducing HAE attacks for 5 of 6 patients with HAE-nC1-INH. No significant safety signals were noted.
Authors
- Claire de Moreuil (ORCID: https://orcid.org/0000-0003-1142-0978)
- Sébastien Sanges (ORCID: https://orcid.org/0000-0003-0280-411X)
- Isabelle Boccon‐Gibod (ORCID: https://orcid.org/0000-0002-5774-8429)
- Matthew Buckland (ORCID: https://orcid.org/0000-0002-5646-4707)
Institutions
- Inserm (FR)
- Barts Health NHS Trust (GB)
- Université de Lille (FR)
- Royal London Hospital (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- Laboratoire National de Référence (MA)
- Lille Inflammation Research International Center (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jacig.2025.100575
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 1.63